Long noncoding RNA MALAT1: a potential novel prognostic biomarkers in cancers based on Meta-analysis.
- Author:
Wei SONG
1
;
Kai WANG
1
;
Runjin ZHANG
1
;
Shubing ZOU
1
Author Information
1. Department of Hepatobiliary Surgery, Second Affiliated Hospital of Nanchang University, Nanchang 330000, China.
- Publication Type:Journal Article
- MeSH:
Biomarkers, Tumor;
genetics;
Humans;
Neoplasms;
genetics;
mortality;
Prognosis;
RNA, Long Noncoding;
Survival Rate
- From:
Journal of Central South University(Medical Sciences)
2016;41(11):1163-1167
- CountryChina
- Language:Chinese
-
Abstract:
To systematically review the potential value of long noncoding RNA (lncRNA) metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) as a potential novel prognostic biomarker in cancers.
Methods: Databases including Cochrane Library, Medline, Embase, PubMed databases were searched for all English studies, which explored the correlation between lncRNA MALAT1 expression and overall survival in tumors. The retrieval time was from inception to August 1, 2015. Two reviewers independently screened literature according to the inclusion and exclusion criteria, extracted data, and assessed methodological quality. Then, Meta-analysis was performed using RevMan 5.3 software.
Results: Ten studies covered a total of 1 016 patients. Meta-analysis showed that high expression of MALAT1 was significantly correlated to poor overall survival (OS) in patients with tumor (HR= 2.08, 95% CI 1.74 to 2.48, P<0.001).
Conclusion: LncRNA MALAT1 might be a potential novel prognostic biomarker in tumor.
